[ET Net News Agency, 18 January 2018] Morgan Stanley lifted its target price for New
China Life Insurance (NCI)(01336) to HK$57 from HK$53, and maintained its "equal-weight"
rating.
The research house said the industry is making gradual changes to adapt a new operating
environment in 2018, demand for insurance remains intact and healthy. Valuation should
continue to re-rate for solid names and Morgan maintained its "attractive" industry view.
It noted that NCI re-rated materially from its lows, up 127%, as the company executed on
its transition plan to become a quality play. The company is focusing on improving margin
by selling more health insurance and delivering above industry growth, which can be more
difficult to achieve.
Morgan belives that NCI will likely face more challenges to meet its high targets as
competition in the health insurance segment is intensifying. Earnings growth could also
lag peers due to its low return in-force book and higher costs. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01336 NCI
Nominal 
14.760 +0.440 (+3.073%) Others
18/01/2018 17:44
[I-bank focus]Morgan ups New China Life (01336) to HK$57
| Remark: | Real time quote last updated: 26/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |